Join Deloitte at 2022 Financial Times Global Pharma and Biotech Summit, an industry-leading conference which brings together the world’s biggest pharma companies and other major organisations across the life sciences and health care value chain. The annual event is essential for you to stay on top of the latest trends and innovations in life sciences. CEOs, policymakers and thought leaders from around the world will explore new frontiers for business and for health care and discuss what’s new in areas such as drug discovery, clinical trials and market access.
While the life sciences and health care industry is witnessing a technological innovation since the pandemic, how is the competition between pharma companies and institutional investors for biotech platforms evolving? The industry is already transforming the clinical trial landscape and leveraging health care intelligence, but is scientific complexity still a hurdle? At the same time, the role of companies’ ethics, sustainability and customer value factors could be at the heart of any responsible business strategy. Deloitte leaders, along with industry peers, will unpack many of these critical questions and more at this year’s conference.
Deloitte is proud to once again be a lead sponsor and is pleased to offer a discounted registration to this year’s conference.
Showing Leadership: What does a good workforce transformation strategy look like? How do pharma companies set ESG goals? How do CEOs make the big calls on where to focus investment?
Supporting Innovation: Will cross-industry collaboration continue beyond the pandemic? How is technology transforming R&D? What are the latest next-generation therapies?
Saving Lives: What does the rise of precision medicine look like? How can pharma companies become more patient-centric? How can high-cost treatments be made more accessible and affordable?
Deloitte participation sessions
Partnerships—Driving innovation through collaboration
What are the emerging opportunities for stakeholders to build partnerships and how do we predict the shift in balance of in-house and outsourced R&D?
Panelists:
David Loew, CEO, Ipsen
Ger Brophy, Executive Vice President, Biopharma Production, Avantor
John Haughey, Global Life Sciences & Health Care Consulting Leader, Deloitte
Kate Bingham, Managing Partner, SV Health Investors
Nerida Scott, Head of J&J Innovation EMEA, Johnson & Johnson
Moderator: Clive Cookson, Science Editor, Financial Times
Translating social determinants of health to business models
What is the case for using data on social determinants of health across different stages of the pharma-biotech value chain, from drug development to patient access?
Panelist:
Lu Zheng, Head EUCAN Value Based Partnerships and Patient Services, Takeda
Marie- Andrée Gamache, Country President, Novartis UK and Ireland
Laura Steele, President and General Manager, Lilly UK, Ireland, and Northern Europe Hub, Eli Lilly
Moderator: Greg Reh, Global Life Sciences and Health Care Industry Leader,Deloitte
What are the most likely developments in pricing and market access for high-cost advanced therapies and what can be done to increase access and affordability in emerging markets?
Panelists:
Jayasree K. Iyer, CEO, Access to Medicine Foundation
Richard Saynor, CEO, Sandoz
Ana Plata, Global Pricing Head, BioPharmaceuticals, AstraZeneca
Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry
Moderator: Vicky Levy, Global Life Sciences Sector Leader, Deloitte
